In this Issue:
T-VEC + ipilimumab in patients with advanced melanoma
Sequential nivolumab and ipilimumab with a planned switch in patients with advanced melanoma
TBI + adoptive transfer of tumourinfiltrating lymphocytes for patients with metastatic melanoma
Dermatologic complications of anti-PD-1/ PD-L1 antibodies
Validity and reliability of dermoscopic criteria for melanoma detection
Evaluation of the MPATH-Dx scheme for diagnosis of cutaneous melanocytic neoplasms
MEK/Plk1 inhibitor combination has synergistic anti-tumour activity in NRAS mutant melanoma
Pembrolizumab for patients with melanoma or NSCLC and untreated brain metastases
Skin self-examination and long-term melanoma survival
Role of MC1R variants in melanoma risk independent of UV radiation exposure
Please login below to download this issue (PDF)